EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy

Chiara Sarlo, Francesco Buccisano, Luca Maurillo, Mariagiovanna Cefalo, Luigi Di Caprio, Laura Cicconi, Concetta Ditto, Licia Ottaviani, Ambra Di Veroli, Maria Ilaria Del Principe, Maria Assunta Grasso, Daniela Nasso und 3 weitere

Leukemia Research and Treatment · 2013

DOI: 10.1155/2013/705714 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia Research and Treatment, 2013. Verfasst von Chiara Sarlo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We explored the safety and efficacy of bortezomib given as single agent in patients with untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional chemotherapy. Fourteen patients were treated with bortezomib 1.5 mg/m 2 administered twice weekly for two weeks, every 3 weeks. Median age was 70 years (range 60–81) and the median number of cycles delivered was 2 (range 1–4). Of 13 evaluable patients, in 8 (61%), the administration of bortezomib resulted in an antileukemic effect as demonstrated by peripheral blood and/or bone marrow blast reduction. In 4 (50%) of these 8, a decrease by 37% of transfusion requirement was also observed . Overall median survival was 4 months (range 0.25–10). Neurotoxicity was the most frequent adverse event with 7 of 13 (54%) patients experiencing grades 3-4 peripheral neuropathy. Neurotoxicity led to treatment discontinuation in 4 (57%) of 7. In conclusion, the observed anti-leukemic activity of bortezomib indicates that there is room for designing additional studies in which combination with other chemotherapeutic agents should be considered. Clinical registration no.: EUDRACT 2006-006923-38.

Autor:innen und Institutionen

  • Department of Hematology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.

Zitieren

APA

Sarlo, C., Buccisano, F., Maurillo, L., Cefalo, M., Di Caprio, L., Cicconi, L., Ditto, C., Ottaviani, L., Di Veroli, A., Del Principe, M. I., Grasso, M. A., Nasso, D., De Santis, G., Amadori, S., & Venditti, A. (2013). Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia Research and Treatment. https://doi.org/10.1155/2013/705714

Vancouver

Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, et al. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia Research and Treatment. 2013. doi:10.1155/2013/705714

BibTeX
@article{Sarlo2013,
  author = {Sarlo, Chiara and Buccisano, Francesco and Maurillo, Luca and Cefalo, Mariagiovanna and Di Caprio, Luigi and Cicconi, Laura and Ditto, Concetta and Ottaviani, Licia and Di Veroli, Ambra and Del Principe, Maria Ilaria and Grasso, Maria Assunta and Nasso, Daniela and De Santis, Giovanna and Amadori, Sergio and Venditti, Adriano},
  title = {Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy},
  journal = {Leukemia Research and Treatment},
  year = {2013},
  doi = {10.1155/2013/705714}
}
Kostenlos starten →